SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.840
+0.050 (1.32%)
At close: Mar 9, 2026, 4:00 PM EDT
3.880
+0.040 (1.04%)
After-hours: Mar 9, 2026, 6:00 PM EDT

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Market Capitalization
183178356330340
Upgrade
Market Cap Growth
988.33%408.46%-44.79%113.36%-91.25%-
Upgrade
Enterprise Value
787396627336
Upgrade
Last Close Price
3.843.743.796.885.9078.10
Upgrade
PE Ratio
-13.41----
Upgrade
PS Ratio
1593.84-26.4828.331.245.58
Upgrade
PB Ratio
1.101.181.351.110.968.81
Upgrade
P/TBV Ratio
1.111.181.351.110.968.81
Upgrade
P/OCF Ratio
-----170.89
Upgrade
EV/Sales Ratio
681.07-6.9129.321.145.51
Upgrade
Debt / Equity Ratio
0.040.040.180.100.190.22
Upgrade
Net Debt / Equity Ratio
-0.60-0.60-0.62-0.88-0.29-0.64
Upgrade
Net Debt / EBITDA Ratio
1.981.980.421.480.362.07
Upgrade
Net Debt / FCF Ratio
1.981.980.472.000.362.76
Upgrade
Asset Turnover
--0.020.030.360.88
Upgrade
Quick Ratio
9.139.132.615.231.371.56
Upgrade
Current Ratio
9.469.462.985.451.471.90
Upgrade
Return on Equity (ROE)
14.96%14.96%-81.92%-95.51%-53.85%-44.21%
Upgrade
Return on Assets (ROA)
-28.20%-28.20%-41.86%-35.30%-27.37%-12.16%
Upgrade
Return on Capital Employed (ROCE)
-30.20%-30.20%-118.50%-52.10%-80.50%-24.50%
Upgrade
Earnings Yield
-2.35%7.46%-97.39%-66.52%-63.04%-5.05%
Upgrade
FCF Yield
-20.56%-25.67%-98.89%-39.91%-86.20%-2.64%
Upgrade
Buyback Yield / Dilution
-11.66%-562.28%-67.74%-26.86%-59.20%-1.21%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.